CRISPR rises after experimental therapy cuts harmful cholesterol levels by half in small study

Crispr Therapeutics AG

10/11/2025 11:15

** U.S.-listed shares of Crispr Therapeutics CRSP.BN rise 5.9% to $58.36 premarket

** Co says early-stage trial of its experimental gene-editing treatment, CTX310, showed reductions in cholesterol and triglyceride levels

** A single-course treatment with CTX310
reduced
 levels of harmful LDL cholesterol and triglycerides by half in those taking the highest dose and showed it was safe to use

** CTX310 works by switching off a gene called ANGPTL3 through a single, two-hour infusion

** Results from the 15-patient trial were presented on Saturday at the American Heart Association meeting in New Orleans and published in the New England Journal of Medicine

** Up to Thursday’s close, stock up ~40% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))